|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0070 - 0.0079|
|52 Week Range||0.0040 - 0.2000|
|PE Ratio (TTM)||-0.20|
|Earnings Date||Mar 17, 2017 - Mar 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.60|
WALTHAM, Mass., Aug. 14, 2017-- Interleukin Genetics, Inc. today announced it has filed a Form 15 with the Securities and Exchange Commission completing the process of delisting and deregistering its securities ...
WALTHAM, Mass., Aug. 04, 2017-- Interleukin Genetics, Inc. today announced it has filed a Form 25 with the Securities and Exchange Commission in furtherance of its plan to delist and deregister its securities ...
Categories: Yahoo Finance Get free summary analysis Interleukin Genetics, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Interleukin Genetics, Inc. – Psychemedics Corporation, Genomic Health, Inc., RadNet, Inc., Quest Diagnostics Incorporated, Myriad Genetics, Inc. and Trovagene, Inc. (PMD-US, GHDX-US, RDNT-US, DGX-US, MYGN-US and TROV-US) that ... Read more (Read more...)